Recovery · Reference
KLOW for Men: Sport, Hormones, Injuries, Hair and What the Research Covers
This page covers what KLOW is, what each component's research does and does not show, the questions men ask most (sport, hormones, testosterone therapy, old injuries, inflammation, hair and fertility), the cautions, and how Pepti supplies it. For the product reference see what is KLOW; for the evidence claim by claim, KLOW benefits.
Treatments mentioned
No study has tested KLOW in men, or in anyone: it is four separately studied peptides, GHK-Cu, KPV, BPC-157 and TB-500, in one vial, and the evidence is per component and mostly animal and cell work. For men the first question is sport: BPC-157 and TB-500 are both named on the 2026 WADA Prohibited List and prohibited at all times, in and out of competition, so KLOW is not an option for anyone in a testing pool. None of the four is a hormone or a growth hormone secretagogue, so KLOW does not raise testosterone or growth hormone, and nothing in its research acts on DHT, the signal behind male pattern hair loss. What KLOW adds over the three-peptide GLOW is KPV, an anti-inflammatory fragment with no human trials. Compounded KLOW is a prescription injection and is not FDA approved.
This page covers what KLOW is, what each component's research does and does not show, the questions men ask most (sport, hormones, testosterone therapy, old injuries, inflammation, hair and fertility), the cautions, and how Pepti supplies it. For the product reference see what is KLOW; for the evidence claim by claim, KLOW benefits.
KLOW for Men
The short answer
| Question | What the research shows | Strength of evidence |
|---|---|---|
| Has KLOW been studied in men? | No study of the blend in anyone | None for the combination |
| Can tested athletes use it? | No: BPC-157 (S0) and TB-500 (S2.3) are prohibited at all times on the 2026 WADA List | Settled |
| Does it raise testosterone or growth hormone? | No; none of the four is a hormone or a secretagogue | Clear: not its mechanism |
| Tendon and muscle repair | Rat Achilles tendon and muscle injury models, mostly BPC-157 | Animal only; no human trial |
| Inflammation | KPV in mouse colitis and cell models | Animal and cell only; no human trial of KPV |
| Hair | Rodent and dish studies of copper peptides and thymosin beta-4; nothing on DHT | Weak, and not pattern hair loss |
| Skin | Topical GHK-Cu cosmetic studies, mostly in women | Small human studies of creams, not the injection |
The honest summary: a rationale built from four animal and cell literatures, no human trial of the blend, and a hard stop for anyone who is drug tested.
KLOW for Men
What KLOW is
| Component | Per vial | Per 25 unit dose | What it is |
|---|---|---|---|
| GHK-Cu | 50 mg | 2.5 mg | Copper-binding tripeptide found in human plasma |
| KPV | 10 mg | 0.5 mg | The last three amino acids of alpha-melanocyte-stimulating hormone |
| BPC-157 | 10 mg | 0.5 mg | 15-amino-acid fragment of a protein from human gastric juice |
| TB-500 | 10 mg | 0.5 mg | Synthetic fragment of thymosin beta-4 |
The rationale prescribers give is that tissue repair runs in overlapping phases (inflammation, cell migration, new blood vessels, matrix synthesis and remodelling) and each component is described as acting on a different one. KPV is placed at the inflammation stage, on the logic that inflammation which never resolves is a common reason repair stalls. That is a rationale, not a finding: no study has confirmed the four act in sequence when injected together. By mass, KLOW is mostly GHK-Cu, 50 of the 80 mg in the vial, and the proportions are fixed.
KLOW for Men
What changes for men
Tested sport: the first question
The 2026 World Anti-Doping Code Prohibited List names BPC-157 in S0, Non-Approved Substances, and lists "Thymosin-ß4 and its derivatives e.g. TB-500" under S2.3, growth factors. Both are prohibited at all times, in and out of competition, and both classifications carry forward on the 2027 List. A blend is prohibited by virtue of its components, so KLOW is prohibited regardless of what KPV and GHK-Cu are. The NCAA names BPC-157 and TB-500 as examples in its banned class too.
There is no off-season: using KLOW in a rehab block months from any event is a violation exactly as much as using it the week of a competition. A prescription does not create an exemption. If you are in any testing pool, tell your physician; KLOW is not prescribed into that situation. The detail is in is TB-500 banned in sports, is BPC-157 banned and peptides for athletes.
Hormones: KLOW does not raise testosterone or growth hormone
None of the four components is a hormone or a growth hormone secretagogue. KLOW does not act on testosterone, growth hormone or IGF-1. BPC-157 is often misdescribed here: a 2014 cell study in Molecules reported higher growth hormone receptor expression in tendon fibroblasts, which makes those cells more responsive to growth hormone already present, not a rise in growth hormone. KPV comes from alpha-MSH but keeps only its anti-inflammatory activity, not its hormonal or pigment effects. Products that act on growth hormone release are things like CJC-1295 / Ipamorelin and sermorelin; the one peptide with research on testosterone is covered in kisspeptin for men.
If you are on testosterone therapy
The repair peptides do not touch the markers testosterone therapy is monitored on. Still, no study has looked at KLOW alongside testosterone, so list it on your intake and tell whoever prescribes your testosterone; the principle in can you take peptides with testosterone is that every prescriber involved should know about the other. For men whose training is capped by an old injury rather than by hormone levels, a repair peptide addresses a different problem than any hormone does.
Tendons, muscles and old injuries
The injury case rests on BPC-157 and, by extension from the full-length protein, on TB-500. A 2003 paper in the Journal of Orthopaedic Research reported faster reattachment and better functional recovery after Achilles tendon transection in rats, and a 2011 paper in the Journal of Applied Physiology reported greater tendon outgrowth and faster cell migration in rat tendon explants and cultured fibroblasts. Animal muscle crush models report faster functional recovery. For TB-500 the case is inferred from thymosin beta-4 wound-healing work.
There are no randomized controlled trials of BPC-157 or TB-500 in humans for tendon or soft-tissue injury. For tendinopathy, progressive loading under a physiotherapist has human trial evidence behind it, which none of KLOW's components does, and a complete rupture or displaced fracture is a surgical question. For a single tendon or ligament problem with no skin or inflammation goal, physicians frequently choose the two-peptide BPC-157 + TB-500 stack over KLOW. More in peptides for tendon and ligament injuries.
Inflammation: what KPV adds
KPV is what separates KLOW from GLOW. Cell and animal studies describe it interfering with NF-kB signalling and reducing pro-inflammatory cytokines such as TNF-alpha and IL-6, and a 2008 paper in Gastroenterology reported reduced inflammation in mouse colitis models, with KPV taken up into gut cells by the PepT1 transporter; much of that work gave KPV in drinking water rather than by injection. There is no human trial of KPV for any indication.
If persistent inflammation is part of the picture, that is the case prescribers make for KLOW over GLOW. If inflammation is systemic rather than tied to an injury, KPV on its own is aimed at it more directly; if the complaint is gut-led, BPC-157 alone is the component with the gastrointestinal literature. The comparisons are in KLOW vs GLOW, KPV vs KLOW and BPC-157 vs KLOW.
Hair
The hair research for KLOW's components is copper-peptide follicle work in mice and rats (1991 and 1993), a 2007 dish study of human follicles using a related copper tripeptide, and a 2004 FASEB Journal paper reporting that thymosin beta-4 increased hair growth in rats and mice by acting on follicle stem cells. BPC-157 and KPV have no hair research. The one human trial involving GHK in men, a 2016 Annals of Dermatology study in 45 men with pattern hair loss, tested a topical GHK combination without copper, not KLOW.
Male pattern hair loss is driven by DHT, and nothing in KLOW's research acts on it. KLOW is not a treatment for pattern hair loss and not a substitute for established hair-loss medications. GHK-Cu for men and peptides for hair growth cover this.
Skin and pigment
KPV is the fragment of alpha-MSH that keeps the anti-inflammatory signalling and drops the pigmentation effect, so KLOW is not expected to darken skin or moles. Any darkening is a reason to stop and report it. The product that does drive pigmentation, Melanotan II, is not in KLOW.
Fertility
None of the four components has human fertility data. Nothing in their research describes an effect on sperm, on the reproductive hormone axis or on conception. That is an absence of data, not evidence of safety. If you are trying to conceive with a partner, tell your physician; see do peptides affect fertility.
KLOW for Men
What the evidence does not establish
- That four peptides together do more than any one alone. No study has compared the blend with its components.
- Any effect in men specifically. There are no sex-specific findings for the blend.
- That KPV does anything in people; it has no human trials.
- That injected GHK-Cu does for skin what topical GHK-Cu is reported to do.
- Any effect on testosterone, growth hormone or male pattern hair loss.
- An effect size or a timeline for any goal. Prescriber timelines are clinical experience, not trial endpoints.
- Long-term safety over years of use.
KLOW for Men
Side effects and cautions
Nothing in the published research suggests the profile differs between men and women.
| What is reported or relevant | How often | What to do |
|---|---|---|
| Injection-site redness, itching, mild soreness, occasional bruising | The most common | Rotate sites; mention it at follow-up |
| A faint blue-green mark at the site | Common | Copper from GHK-Cu; clears on its own |
| Early nausea, a metallic taste, light-headedness or flushing | Uncommon | Message your care team if it persists, especially if you take blood-pressure medication |
| Tiredness, head fog or headache in the first week or two | Some people | Usually settles; report it if it does not |
| Persistent vomiting, abdominal pain, jaundice or new confusion | Not reported at prescribed doses | The pattern copper excess would produce; stop and contact your care team the same day |
| Facial or throat swelling, widespread rash, difficulty breathing | Rare | Call 911 or go to emergency care first, then tell your care team |
| Situation | Why it matters |
|---|---|
| In a drug-testing pool | BPC-157 and TB-500 are prohibited at all times |
| Wilson's disease or another copper disorder | GHK-Cu delivers copper; rules KLOW out |
| High-dose zinc | Zinc competes with copper; list your dose |
| Anticoagulants | BPC-157's vascular mechanism and animal clotting signals |
| Personal history of cancer | The components are described as supporting new blood-vessel growth |
| Liver disease or heavy drinking | The liver clears copper; see can you drink alcohol on KLOW |
| Another GHK-Cu product | Every GHK-Cu blend carries a full 50 mg; two at once doubles the copper |
More in KLOW side effects.
KLOW for Men
How Pepti supplies KLOW, and the alternatives
| Product | What is in it | Typical directions | Price |
|---|---|---|---|
| KLOW Blend | 5 mL vial: GHK-Cu 10 mg/mL + KPV 2 mg/mL + BPC-157 2 mg/mL + TB-500 2 mg/mL (50 / 10 / 10 / 10 mg) | 0.25 mL (25 units) subcutaneously Monday through Friday mornings | $259/mo |
| GLOW | The same minus KPV: 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 | 0.25 mL (25 units) Monday through Friday mornings | $259/mo |
| BPC-157 + TB-500 | 5 mL vial: 5 mg BPC-157 and 5 mg TB-500 | Printed on your vial | $259/mo |
| KPV | 5 mL vial: 10 mg KPV | Printed on your vial | $229/mo |
A KLOW vial holds 20 doses at 25 units, about four weeks, so refills run every 28 days, one vial per fill. KLOW also comes as a pre-filled 3 mL Pen cartridge with the same four peptides at the same totals. Your physician sets your directions after reviewing your intake, and they are printed on the vial. The dose math is in KLOW dosage.
Every price is all-in, covering medication, physician review, refill management and shipping, with no membership fee. Pepti is cash-pay and does not bill insurance. Vials arrive as solutions ready to use, with sterile syringes and alcohol prep pads, shipped refrigerated with ice packs.
KLOW for Men
Where KLOW stands with the FDA
KLOW has no regulatory status of its own; its components do. On 15 April 2026 the FDA removed BPC-157, KPV, TB-500 and injectable GHK-Cu from Category 2 of its interim 503A list. On 23 July 2026 the FDA's advisory committee voted 8 to 6, with one abstention in each case, to recommend adding BPC-157, KPV and TB-500 to the 503A Bulks List; the FDA's final determination is pending. GHK-Cu is scheduled for review at a meeting before the end of February 2027. Compounded medications are not FDA approved.
KLOW for Men
Where to get KLOW prescribed
KLOW cannot be bought legitimately without a prescription. Sites shipping it without one are selling a research-use-only product, where no pharmacy is accountable for identity, purity, sterility or concentration. The prescription route:
- Complete a free online intake covering your history, medications, supplements, testosterone therapy if any, whether you are drug tested, and the injury or goal.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are at /quality/lab-results.
- It ships refrigerated with your directions printed on the vial.
- Your care team stays reachable for questions and side effects.
Step by step: how to get KLOW prescribed online. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The wider picture is in peptides for men over 40.
References
What this is based on.
References
- Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts · Molecules (2014) · PMID 25415472
- Krivic A, Anic T, Seiwerth S, et al.. Achilles detachment of rat and stable gastric pentadecapeptide BPC 157 · Journal of Orthopaedic Research (2006) · PMID 16583442
- Sikiric P, Seiwerth S, Rucman R, et al.. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract · Current Pharmaceutical Design (2011) · PMID 21548867
- Cerovecki T, Bojanic I, Brcic L, Radic B, et al.. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat · J Orthop Res (2010) · PMID 20225319
- Sikiric P, Seiwerth S, Rucman R, Turkovic B, et al.. Stable gastric pentadecapeptide BPC 157-NO-system relation · Curr Pharm Des (2014) · PMID 23755725
- Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H · Drug Test Anal (2017) · PMID 28035768
- Thomas A, Görgens C, Guddat S et al.. Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry · J Sep Sci (2016) · PMID 26578461
- Farrar JT, Young JP Jr, LaMoreaux L, Werth JL et al.. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale · Pain (2001) · PMID 11690728
- Meyer JD, Ho B, Manning MC. Effects of conformation on the chemical stability of pharmaceutically relevant polypeptides · Pharm Biotechnol (2002) · PMID 11987755
- Xu C, Sun L, Ren F, Huang P, et al.. Preclinical Safety Evaluation of Body Protective Compound-157, a Potential Drug for Treating Various Wounds · Regul Toxicol Pharmacol (2020) · PMID 32334036
- He L, Feng D, Guo H, et al.. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs · Front Pharmacol (2022) · PMID 36588717
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain · Altern Ther Health Med (2021) · PMID 34324435
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
KLOW for Men, answered.
No study has tested KLOW in men or anyone. Each component has animal and cell research, and GHK-Cu has small topical skin studies, mostly in women. Any benefit for men is described in preclinical research, not established in people.
Not if they are drug tested. BPC-157 is named under S0 and TB-500 under S2.3 on the 2026 WADA Prohibited List, both prohibited at all times, and the NCAA names both as examples in its banned class.
No. None of the four components is a hormone or a secretagogue, and BPC-157's growth hormone receptor finding in tendon cells is not a rise in any hormone level.
No interaction is described, but no study has looked at the combination. List both on your intake and tell whoever prescribes your testosterone.
KLOW is not a muscle-building product. Its components are studied around repair, inflammation and skin, and nothing in its research describes building muscle. See peptides for muscle growth and recovery.
They have not been compared. The only difference is KPV, the anti-inflammatory component. If persistent inflammation is part of the picture, prescribers describe KLOW as the fuller formula; if not, GLOW covers the repair case with one fewer peptide.
Not in the way established hair-loss medications do. Pattern loss is driven by DHT, and nothing in KLOW's research acts on it. The hair evidence for its components is rodent and dish work.
None of the four components has human fertility data, which is an absence of data rather than reassurance. Tell your physician if you are trying to conceive with a partner.
It is not expected to. KPV keeps alpha-MSH's anti-inflammatory signalling without its pigmentation effect. Report any darkening of skin or moles.
The same as for women: mostly injection-site redness, soreness or bruising, sometimes a faint blue-green mark, and in some people early nausea, light-headedness, tiredness or headache. Persistent vomiting, abdominal pain, jaundice or new confusion is a same-day call.
At Pepti, KLOW is $259 a month, all-in, covering medication, physician review, refill management and shipping.
No. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.